Participants start on a lower dose, such as 2mg once weekly, before gradually increasing to the target dose being studied
Occasionally, and for unknown reasons, a person might be unable to tolerate even a small dose of a GLP-1 agonist, requiring an alternative approach
Inclusion criteria were original research articles, randomized controlled trials, and clinical trials that examined the clinical effects or pharmacokinetics of carnitine supplementation in hemodialysis patients
The class of drugs that includes Ozempic, Wegovy, Mounjaro, and now countless others Zepbound, compound GLP-1s, etc
notably, metformin non-users experienced numerically higher gastrointestinal event rates
Phase 4: 1.7mg weekly (weeks 13 through 16) This dose pushes deeper into appetite suppression territory